KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $12.2 million.

  • CRISPR Therapeutics AG's Change in Accured Expenses rose 13190.76% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 21397.08%. This contributed to the annual value of -$27.3 million for FY2024, which is 3475.08% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Change in Accured Expenses stood at $12.2 million, which was up 13190.76% from -$14.7 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Change in Accured Expenses' 5-year high stood at $43.0 million during Q1 2025, with a 5-year trough of -$38.2 million in Q3 2024.
  • Its 5-year average for Change in Accured Expenses is $1.9 million, with a median of $1.3 million in 2021.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Change in Accured Expenses surged by 204073.51% in 2022 and then plummeted by 25838.81% in 2025.
  • CRISPR Therapeutics AG's Change in Accured Expenses (Quarter) stood at $22.8 million in 2021, then tumbled by 236.5% to -$31.1 million in 2022, then soared by 70.44% to -$9.2 million in 2023, then rose by 14.59% to -$7.8 million in 2024, then surged by 255.1% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, -$14.7 million for Q2 2025, and $43.0 million during Q1 2025.